Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate

FREMONT, Calif., Jan. 8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that it has initiated patient dosing in its Phase I/II clinical trial evaluating its systemically administered siRNA drug candidate QPI-1002 (previously referred to as DGFi) for prevention of Delayed Graft Function (DGF) in patients undergoing deceased donor kidney transplantation. DGF represents Quark's second indication being evaluated for the systemically administered dug candidate in human clinical trials. This trial follows two currently enrolling Phase I clinical trials in acute kidney injury (AKI).

The multi-center, two-part Phase I/II clinical trial in DGF is expected to enroll up to 204 adult kidney transplant recipients. The first part of the study is a dose-escalation design to evaluate the safety and tolerability of a single intravenous injection of QPI-1002 in renal transplant patients at high risk to develop DGF. The second part of the study will evaluate safety and potential clinical activity of a selected dose of QPI-1002 in the same patient population. Patients will be enrolled in clinical sites in the United States.

Shai Erlich, Ph.D., Chief Medical Officer of Quark, commented, "The initiation of patient dosing with QPI-1002 is an important milestone for Quark as well as being an innovative approach to offer therapeutic benefit to adult kidney transplant patients at high risk for developing DGF. The siRNA drug candidate is based on the proprietary concept of Quark and reflects Quark's success in developing products originating from conceptually novel internal developments. These accomplishments further validate Quark's ability to advance innovative product candida
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014 The legalization of medical and recreational ... as a new economic driver – that has taken ... the right response to the will of the people ... At a National Press Club Newsmakers news conference ... experts in the area of marijuana legalization will discuss ...
(Date:7/14/2014)... 2014 Lumin Medical LLC, a healthcare IT ... the leading provider of on-demand patient tracking solutions and ... to Franklin, Wis. ... light and our mission is to provide visibility for ... and reduce costs," said James Hermann , President ...
(Date:7/14/2014)... 14, 2014 Valeant Pharmaceuticals International, Inc. ... today announced it has filed a premerger notification ... (HSR) with the U.S. Federal Trade Commission (FTC) ... (NYSE: AGN). About Valeant Pharmaceuticals ... Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical ...
Breaking Medicine Technology:NPC Newsmaker Program: Interpreting smoke signals from the marijuana skirmish line 2Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 4Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 5
... Approximately ninety-one percent of dentists say patients complaining about dry ... survey conducted by the Academy of General Dentistry (AGD). ... decrease in salivary function. It affects approximately one in ... risk for tooth decay. During the Academy of General Dentistry,s ...
... Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that ... July 9, 2009 at 8:00 am EDT (5:00 am PDT). ... investigator of the trial will discuss results of the Company,s ... the Company,s plans for further development and related matters. ...
Cached Medicine Technology:Dry Mouth Linked to Prescription and Over the Counter Drugs 2Dry Mouth Linked to Prescription and Over the Counter Drugs 3Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 2
(Date:7/14/2014)... 2014 Acute coronary syndrome (ACS) ... healthcare costs, frequent recurrences and hospitalizations, and high ... ACS incidence increases with age and will be ... population increases around the world. ACS is classified ... heart muscle damage inferred from a person’s symptoms, ...
(Date:7/14/2014)... 2014 Midway through summer, throngs of families ... the National Lampoon classic “Vacation.” An estimated four out of ... by Bridgestone Americas , embark on summer road trips. And ... nagging back pain as the result of hours cramped behind ... , “For these patients, riding in a car for an ...
(Date:7/14/2014)... Institutes of Health (NIH) have identified genetic markers associated ... characterized by high levels of immune cells called eosinophils ... are involved in the development of EoE, which can ... allergies. The findings also may help explain why the ... in part by the Consortium of Food Allergy ...
(Date:7/14/2014)... A recent study published in the July 2014 ... of Child and Adolescent Psychiatry confirms the validity ... criterion for diagnosis of attention-deficit/hyperactivity disorder (ADHD). , In ... at 7 in DSM-IV, has been raised to 12. ... set at 12, rather than an earlier age, to ...
(Date:7/14/2014)... years that have passed since acupuncture was first ... used to treat a number of physical, mental ... rehabilitation, headaches, menstrual cramps, asthma, carpal tunnel, fibromyalgia ... Now, a meta-analysis of randomized controlled trials which ... , the journal of The North American Menopause ...
Breaking Medicine News(10 mins):Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 2Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 3Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 4Health News:Top Orthopedic Surgeon Shares Seven Ways To Reduce Back Pain During Long Summer Road Trips 2Health News:Top Orthopedic Surgeon Shares Seven Ways To Reduce Back Pain During Long Summer Road Trips 3Health News:Scientists deepen genetic understanding of eosinophilic esophagitis 2Health News:Bothered by hot flashes? Acupuncture might be the answer 2
... and his colleagues from the Stanford University School of Medicine ... Cancer Research. The result of the study has found that ... to reduce the growth of cancer in patients with prostate ... two drugs reduces the growth of prostate cancer by 70 ...
... researchers from University of South Florida had reported in ... Sciences that the more nature of mental exercise performed ... reducing the risk of dementia in later life.// ... lifetime occupation and risk for Alzheimer’s disease and dementia ...
... Kolkata (6th Sept 2005): In an alarming announcement the ... that West Bengal was facing a Dengue epidemic and the ... last year.// ,Mishra also said that other than ... the people, especially in Kolkata. ,Dengue was also ...
... low dose of Vitamin D with non-steroidal anti- inflammatory ... says a study.// ,David Feldman and other researchers ... a form of Vitamin D, combined with an over-the-counter ... online edition of Ivanhoe Broadcast News. ,The researchers ...
... of had discovered a new way to test the ... attack. // ,The researchers had used a ... cells’ destinations after being injected into the body to ... attack. ,In the study, researchers surgically ...
... from anorexia nervosa have the similar brain activities that ... study was published in the September issue of Archives ... alterations in the activity of serotonin (a brain chemical ... the appetite alteration in anorexia nervosa as well as ...
Cached Medicine News:
... Selecta Duo Adding the ... platform creates the Selecta Duo, ... nm Photocoagulator combination laser that ... involving both the anterior segment ...
Patient-Centered Therapy that promotes natural cardiac function....
... The Apeel CS Catheter Delivery System ... used for the placement of permanent ... Apeel CS Catheter Delivery System is ... torqueability, flexibility, and softness, plus high ...
... Alliance Catheter Delivery System (CDS) ... stabilization of the Aescula LV ... has a patented coronary sinus ... and easy access to the ...
Medicine Products: